Targeting CD19 in Diffuse Large B-Cell Lymphoma

During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

During an in-person Community Case Forum event, Hayder Saeed, MD, discussed the RE-MIND2 matched cohort data and real-world data on the combination of tafasitamab and lenalidomide in patients with diffuse large B-cell lymphoma.

During a Case-Based Roundtable® event, Amitkumar Mehta, MD, discussed the efficacy of loncastuximab in patients who also received CAR T-cell therapy in the first article of a 2-part series.

During a Case-Based Roundtable® event, Amitkumar Mehta, MD, discussed the study design of the LOTIS-2 trial and adverse events related to loncastuximab tesirine in diffuse large B-cell lymphoma in the first article of a 2-part series.

A study found that glofitamab plus gemcitabine and oxaliplatin significantly improved survival in patients with relapsed/refractory diffuse large B-cell lymphoma who were not eligible for stem cell transplant.